Ryan Brown, EVP, General Counsel of Sarepta Therapeutics Inc (NASDAQ:SRPT), sold 38,957 shares of the company on June 25, 2024.
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy. Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.